Broad inhibition of class I PI3Ks results in an unfavorable safety profile with off-target effects (including mood disorders and liver toxicity) limiting the clinical utility of many previous PI3K inhibitors [47]. The gene discussed is PIK3CD; the disease is mood disorder.